Literature DB >> 299812

Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

A G Huvos, G Rosen, R C Marcove.   

Abstract

Twenty patients with osteogenic sarcoma of the distal portion of the femur and the proximal portion of the tibia received chemotherapy (vincristine sulfate, methotrexate with leucovorin calcium rescue, [citrovorum factor; folinade calcium], and doxorubicin hydrochloride [Adriamycin]), followed by radical en bloc resection and prosthetic bone replacement. Histologic examination of surgical specimens obtained after chemotherapy showed variable degrees of tumor destruction and, in some cases, massive tumor necrosis, attesting to the profound effects of vigorous chemotherapy. This new therapeutic regimen, when feasible, may prove to be the treatment of choice in osteogenic sarcoma.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 299812

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  91 in total

Review 1.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

2.  Massive bone allografts in children.

Authors:  R Kohler; F Lorge; M Brunat-Mentigny; D Noyer; L Patricot
Journal:  Int Orthop       Date:  1990       Impact factor: 3.075

3.  Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.

Authors:  V Nataraj; S Rastogi; S A Khan; M C Sharma; S Agarwala; S Vishnubhatla; S Bakhshi
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

4.  Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.

Authors:  M-A Estève; B Devictor-Pierre; G Galy; N André; C Coze; B Lacarelle; J-L Bernard; S Monjanel-Mouterde
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

5.  Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment.

Authors:  K Junker; M Thomas; K Schulmann; F Klinke; U Bosse; K M Müller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results.

Authors:  C Baunin; G Schmidt; K Baumstarck; C Bouvier; J C Gentet; A Aschero; A Ruocco; B Bourlière; G Gorincour; C Desvignes; N Colavolpe; G Bollini; P Auqier; P Petit
Journal:  Skeletal Radiol       Date:  2012-02-09       Impact factor: 2.199

7.  Tumor volume change after chemotheraphy as a predictive factor of disease free survival for osteosarcoma.

Authors:  Seong-Hwan Moon; Kyoo-Ho Shin; Jin-Suck Suh; Woo-Ick Yang; Jae-Keong Noh; Soo-Bong Hahn
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

8.  Combined ultrastructural, histochemical, and autoradiographic study of osteosarcoma after preoperative chemotherapy according to the COSS 80 protocol.

Authors:  E Grundmann; A Roessner; W Schlake; M Immenkamp; P Preusser; G Wüst; J Ritter; E Schnepper
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

9.  Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

Authors:  M Salzer-Kuntschik; G Delling; G Beron; R Sigmund
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

10.  Morphological changes in osteosarcoma after chemotherapy--COSS 80.

Authors:  G Delling; H Krumme; M Salzer-Kuntschik
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.